12
Population pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Mindy L Simpson 1 , Roshni Kulkarni 2 , Carmen Escuriola Ettingshausen 3 , Rikke Medom Meldgaard 4 , David L Cooper 5 , Robert Klamroth 6 Supplement materials 1 1 2 3 4 5 6 7 8 9 10 11

Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Population pharmacokinetic modeling of on-demand

and surgical use of nonacog beta pegol (N9-GP) and

rFIXFc based upon the paradigm 7 comparative

pharmacokinetic study

Mindy L Simpson1, Roshni Kulkarni2, Carmen Escuriola Ettingshausen3, Rikke Medom

Meldgaard4, David L Cooper5, Robert Klamroth6

Supplement materials

1

1

2

3

4

56

7

89

10

11

Page 2: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

212

Page 3: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Supplementary figure 1 Goodness of fit for (A) predicted FIX activity with N9-GP

compared with observed activity in paradigm 7; (B) Residuals vs time with N9-GP in

paradigm 7; (C) Individual vs population predictions of N9-GP compared with observed

activity in paradigm 7.

Abbreviation: FIX, factor IX.

3

1314

15

16

1718

Page 4: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

419

Page 5: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Supplementary figure 2 Goodness of fit for (A) predicted FIX activity with rFIXFc

compared with observed activity in paradigm 7; (B) residuals vs time with rFIXFc in

paradigm 7; (C) individual vs population predictions of rFIXFc compared with observed

activity in paradigm 7.

Abbreviations: FIX, factor IX; rFIXFc, recombinant FIX Fc fusion protein.

5

20

212223

24

25

2627

28

Page 6: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Supplementary figure 3 Predictions of FIX activity with N9-GP compared with

observed activity in paradigm 2.

Abbreviation: FIX, factor IX.

6

2930

31

3233

34

Page 7: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

735

Page 8: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Supplementary figure 4 Predicted means and confidence limits for simulated

dosing for severe bleeds to achieve FIX activities meeting WFH guidelines2 for (A) N9-

GP 80 IU/kg and for (B) rFIXFc 80 IU/kg followed by 50 IU/kg.

Abbreviations: FIX, factor IX; rFIXFc, recombinant FIX Fc fusion protein; WFH, World Federation

of Hemophilia.

8

36

37

38

39

40

4142

Page 9: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

9

Page 10: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Supplementary figure 5 Predicted means and confidence limits for simulated

dosing for life-threatening bleed (N9-GP vs rFIXFc) to achieve FIX activities to meet

WFH guidelines2 for (A) N9-GP 80 IU/kg followed by 40 IU/kg and (B) rFIXFc 110 IU/kg

followed by three doses of 90 IU/kg and seven doses of 80 IU/kg.

Abbreviations: FIX, factor IX; rFIXFc, recombinant FIX Fc fusion protein; WFH, World Federation

of Hemophilia.

10

44

45

46

47

4849

50

Page 11: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

1151

Page 12: Web viewPopulation pharmacokinetic modeling of on-demand and surgical use of nonacog beta pegol (N9-GP) and rFIXFc based upon the paradigm 7 comparative pharmacokinetic study Supplementary

Supplementary figure 6 Predicted means and confidence limits for simulated

dosing for major surgery to achieve FIX activities meeting WFH guidelines2 for (A) N9-

GP 80 IU/kg followed by 40 IU/kg and for (B) rFIXFc 80 IU/kg followed by 50 IU/kg.

Abbreviations: FIX, factor IX; rFIXFc, recombinant FIX Fc fusion protein; WFH, World Federation

of Hemophilia.

12

5253

54

55

5657

58